Flibanserin Powder (167933-07-5) HPLC≥98%

www.wisepowder.com

wise12@wisepowder.com

Flibanserin Powder (167933-07-5) 01

Overview

Flibanserin powder, sold under the trade name Addyi. Flibanserin powder is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. The certainty of the estimate is low.

02

Flibanserin Powder (167933-07-5) video 1/4

www.wisepowder.com

03

wise12@wisepowder.com

Flibanserin Powder (167933-07-5) Base

Information Name

Flibanserin powder

CAS

167933-07-5

Purity

98%

Chemical name

Flibanserin

Synonyms

Flibanserin; Bimt-17; Bimt 17; Addyi

Molecular Formula

C20H21F3N4O

Molecular Weight

390.4 g/mol

Melting Point

/

InChI Key

PPRRDFIXUUSXRA-UHFFFAOYSA-N

Form

Solid

Appearance

White powder

Half Life

≈11 hours

Solubility

Water Solubility 0.178 mg/mL

Storage Condition

Store in a sealed airtight container, keep the air out, protected from heat, light and humidity.

Application

Use for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD)

Testing Document

Available

04

Flibanserin Powder (167933-07-5) General

Description Flibanserin powder, people also search for Addyi, it is a new non-hormonal prescription medication for hypoactive sexual desire disorder (HSDD) in women.

Flibanserin powder is the first medicine ever specifically approved to treat loss of sexual desire in either men or women.

It’s also potentially important for sexual science — since FDA approval of flibanserin is likely to lead to much more research on the neurochemistry of desire.

05

Flibanserin Powder (167933-07-5) History 2/4

www.wisepowder.com

wise12@wisepowder.com

Flibanserin powder is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals.

06

Flibanserin Powder (167933-07-5) Mechanism Of

Action Flibanserin’s mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.

07

Flibanserin Powder (167933-07-5) Application

Flibanserin powder is used to treat women who have not gone through menopause who have low sexual desire and are concerned about it.

Flibanserin powder should not be used to treat low sexual desire caused by: a medical or mental/mood disorder, problems in the relationship, or the effects of other drugs. This medication should not be used by women who have gone through menopause, or by men. Flibanserin powder is not used to enhance sexual performance.

08

Flibanserin Powder (167933-07-5) More research

People may ask “Is Flibanserin safe?” “What are Flibanserin side effects?”

The clinical trials data presented to the FDA on flibanserin included results from over 11,000 patients — one of the largest data-sets ever presented in the FDA’s history. The safety of this medication has been evaluated more stringently than that of most new drugs approved by the FDA. That being said, there is still much that is unknown about flibanserin — as with any other recently-approved medication.

Rare but serious Flibanserin side effects are sometimes only discovered after a drug has been in general use for months or years.

The two Flibanserin side effects that the FDA looked at most carefully before approving flibanserin were sedation, and dizziness or fainting due to a drop in blood pressure.

3/4

www.wisepowder.com

09

wise12@wisepowder.com

Flibanserin Powder (167933-07-5) Document

Download COA

10

Flibanserin Powder (167933-07-5) Reference

[1] “Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee” (PDF). June 4, 2015. Retrieved 5 June 2015.

[2] Invernizzi, Roberto William; Sacchetti, Giuseppina; Parini, Stefania; Acconcia, Sabrina; Samanin, Rosario (2003). “Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1Areceptors”. British Journal of Pharmacology. 139 (7): 1281–1288. doi:10.1038/sj.bjp.0705341. ISSN 0007-1188. PMC 1573953. PMID 12890707.

[3] “Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women”. 27 June 2013.

[4] Pollack, Andrew (2015-06-04). “‘Viagra for Women’ Is Backed by an F.D.A. Panel”.

The New York Times.

4/4